ATE241362T1 - Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält - Google Patents

Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält

Info

Publication number
ATE241362T1
ATE241362T1 AT94927583T AT94927583T ATE241362T1 AT E241362 T1 ATE241362 T1 AT E241362T1 AT 94927583 T AT94927583 T AT 94927583T AT 94927583 T AT94927583 T AT 94927583T AT E241362 T1 ATE241362 T1 AT E241362T1
Authority
AT
Austria
Prior art keywords
estrogen
progestogen
pct
substitution therapy
composition
Prior art date
Application number
AT94927583T
Other languages
English (en)
Inventor
Philippe Robert Marie Koninckx
Original Assignee
Saturnus Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saturnus Ag filed Critical Saturnus Ag
Application granted granted Critical
Publication of ATE241362T1 publication Critical patent/ATE241362T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT94927583T 1993-09-09 1994-09-08 Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält ATE241362T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL9301562A NL9301562A (nl) 1993-09-09 1993-09-09 Preparaat voor substitutietherapie.
PCT/EP1994/002997 WO1995007081A1 (en) 1993-09-09 1994-09-08 Preparation for substitution therapy, containing at least one progestogen and at least one extrogen

Publications (1)

Publication Number Publication Date
ATE241362T1 true ATE241362T1 (de) 2003-06-15

Family

ID=19862861

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927583T ATE241362T1 (de) 1993-09-09 1994-09-08 Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält

Country Status (12)

Country Link
US (1) US5827843A (de)
EP (1) EP0717626B1 (de)
JP (1) JPH09502194A (de)
KR (1) KR960704553A (de)
CN (1) CN1076969C (de)
AT (1) ATE241362T1 (de)
AU (1) AU708881B2 (de)
DE (1) DE69432752T2 (de)
FI (1) FI961098A (de)
HU (1) HU224818B1 (de)
NL (1) NL9301562A (de)
WO (1) WO1995007081A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
DE19549264A1 (de) * 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
US6506390B2 (en) 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
ES2229378T3 (es) * 1996-07-26 2005-04-16 Wyeth Anticonceptivo oral.
WO1998004246A2 (en) * 1996-07-26 1998-02-05 American Home Prod Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
PL201878B1 (pl) * 2000-01-18 2009-05-29 Bayer Schering Pharma Ag Kompozycja farmaceutyczna w doustnej postaci dawkowania. zawierająca estrogen i drospirenon, zastosowanie kompozycji i preparat farmaceutyczny
HRP20020666B1 (en) * 2000-01-18 2011-07-31 Bayer Schering Pharma Aktiengesellschaft Drospirenone for hormone replacement therapy
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
EP1857110A3 (de) * 2001-03-16 2008-08-06 Wyeth Hormonersatztherapie
IL157944A0 (en) * 2001-03-16 2004-03-28 Wyeth Corp Hormone replacement therapy
WO2002092102A2 (en) 2001-05-16 2002-11-21 Endeavor Pharmaceuticals Treatment of conditions relating to hormone deficiencies by administration of progestins
EP1260225A1 (de) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Pharmazeutische Zusammensetzung für die Hormonersatztherapie
US8048869B2 (en) * 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
ATE449606T1 (de) * 2001-05-23 2009-12-15 Pantarhei Bioscience Bv Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
PT1390042E (pt) * 2001-05-23 2008-03-10 Pantarhei Bioscience Bv Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal
WO2003006027A1 (en) * 2001-07-13 2003-01-23 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
WO2003041718A1 (en) * 2001-11-15 2003-05-22 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
PT1453521E (pt) 2001-12-05 2013-10-08 Teva Womens Health Inc Contracetivos orais para prevenir a gravidez e diminuir a sintomatologia pré-menstrual
TW200306196A (en) * 2002-04-03 2003-11-16 Wyeth Corp Hormone replacement therapy
TW200306846A (en) * 2002-04-03 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200306851A (en) * 2002-04-29 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
US7923440B2 (en) * 2002-06-11 2011-04-12 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
US7943604B2 (en) * 2002-06-11 2011-05-17 Pantarhei Bioscience B.V. Method of treating human skin and a skin care composition for use in such a method
AU2003253506A1 (en) 2002-07-12 2004-02-02 Pantarhei Biosciences B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
SI1556058T1 (sl) * 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
CA2771944A1 (en) * 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
CA2674325A1 (en) * 2007-01-08 2008-07-17 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
ITMI20122027A1 (it) * 2012-11-28 2014-05-29 Altergon Sa Soluzioni acquose orali di ormoni steroidei e hp¿cd con biodisponibilità ottimizzata

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1021196C (zh) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
NO301689B1 (no) * 1987-09-24 1997-12-01 Jencap Research Ltd Kontraseptivt preparat i form av en forpakning
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product

Also Published As

Publication number Publication date
JPH09502194A (ja) 1997-03-04
AU708881B2 (en) 1999-08-12
EP0717626B1 (de) 2003-05-28
US5827843A (en) 1998-10-27
KR960704553A (ko) 1996-10-09
AU7695294A (en) 1995-03-27
HU224818B1 (en) 2006-02-28
WO1995007081A1 (en) 1995-03-16
HU9600592D0 (en) 1996-05-28
CN1133011A (zh) 1996-10-09
NL9301562A (nl) 1995-04-03
FI961098A (fi) 1996-04-03
HUT74452A (en) 1996-12-30
FI961098A0 (fi) 1996-03-08
CN1076969C (zh) 2002-01-02
DE69432752T2 (de) 2004-04-08
DE69432752D1 (de) 2003-07-03
EP0717626A1 (de) 1996-06-26

Similar Documents

Publication Publication Date Title
ATE241362T1 (de) Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält
IL111077A (en) Pyridine derivatives processes for the preparation thereof and pharmaceutical compositions containing them
TR27835A (tr) Sübstitüe edilmis azadiokzasikloalkenler.
IL151371A0 (en) Modified porcine factor viii and pharmaceutical compositions containing the same
DE69726577D1 (en) Kristallin form i von clarithromycin
GEP20012530B (en) Neuroactive Steroids of the Androstane and Pregnane Series
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
MX9802130A (es) Agonistas adrenergicos beta3 selectivos.
IL111861A (en) Phenyl-n-substituted azabicycloalkene derivatives and pharmaceutical compositions containing them
DK0733046T3 (da) Benzoylguanidiner, deres fremstilling og anvendelse i medikamenter
CA2024188A1 (en) Method of treating premature ejaculation using sertraline
AU7496894A (en) Antiglucocorticoid steroids for the treatment of anxiety disorders
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
ATE152628T1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
ATE221391T1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
IL112059A0 (en) A transdermal therapeutic composition containing a deuterated active substance
HUT77868A (hu) Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
AU695894B2 (en) Hormonal means for acne therapy and employment thereof
PT1007085E (pt) Utilizacao da hormona de crescimento em composicoes para o tratamento da resistencia a insulina no coracao
DE69109293D1 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
CA2171460A1 (en) Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь
UA30722A (uk) Спосіб профілактики гнійно-септичних ускладнень у породіль

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties